Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology

Handbook of Clinical Neurology

Volumn 116, Issue , 2013, Pages 561-575

  Vucic, Steve ^a,c   Kiernan, Matthew C ^b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Amyotrophic lateral sclerosis; Cortical hyperexcitability; Dying forward; Glutamate excitotoxicity; Short interval intracortical inhibition

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; ARTICLE; CORTICAL HYPEREXCITABILITY; DYING FORWARD; EVOKED MUSCLE RESPONSE; GLUTAMATE EXCITOTOXICITY; HUMAN; METHODOLOGY; MOTOR CORTEX; PATHOPHYSIOLOGY; PHYSIOLOGY; PYRAMIDAL TRACT; SHORT-INTERVAL INTRACORTICAL INHIBITION; TRANSCRANIAL MAGNETIC STIMULATION; UTILIZATION REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; CORTICAL HYPEREXCITABILITY; DYING FORWARD; GLUTAMATE EXCITOTOXICITY; SHORT-INTERVAL INTRACORTICAL INHIBITION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; EVOKED POTENTIALS, MOTOR; HUMANS; MOTOR CORTEX; PYRAMIDAL TRACTS; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84885087606     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53497-2.00045-0     Document Type: Chapter

References (177)

1. Alexianu M.E., Ho B.K., Mohamed A.H., et al. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1994, 36:846-858.
2. Amassian V.E., Stewart M., Quirk G.J., et al. Physiological basis of motor effects of a transient stimulus to cerebral cortex. Neurosurgery 1987, 20:74-93.
3. Armand J. The origin, course and terminations of corticospinal fibers in various mammals. Prog Brain Res 1982, 57:329-360.
4. Attarian S., Azulay J.P., Lardillier D., et al. Transcranial magnetic stimulation in lower motor neuron diseases. Clin Neurophysiol 2005, 116:35-42.
5. Attarian S., Vedel J.P., Pouget J., et al. Cortical versus spinal dysfunction in amyotrophic lateral sclerosis. Muscle Nerve 2006, 33:677-690.
6. Avoli M., Hwa G., Louvel J., et al. Functional and pharmacological properties of GABA-mediated inhibition in the human neocortex. Can J Physiol Pharmacol 1997, 75:526-534.
7. Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994, 330:585-591.
8. Berardelli A., Inghilleri M., Cruccu G., et al. Electrical and magnetic transcranial stimulation in patients with corticospinal damage due to stroke or motor neurone disease. Electroencephalogr Clin Neurophysiol 1991, 81:389-396.
9. Boillee S., Vande Velde C., Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
10. Bondy S.C., Lee D.K. Oxidative stress induced by glutamate receptor agonists. Brain Res 1993, 610:229-233.
11. Boroojerdi B., Battaglia F., Muellbacher W., et al. Mechanisms influencing stimulus-response properties of the human corticospinal system. Clin Neurophysiol 2001, 112:931-937.
12. Boston-Howes W., Gibb S.L., Williams E.O., et al. Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J Biol Chem 2006, 281:14076-14084.
13. Brouwer B., Ashby P. Corticospinal projections to upper and lower limb spinal motoneurons in man. Electroencephalogr Clin Neurophysiol 1990, 76:509-519.
14. Browne S.E., Yang L., DiMauro J.P., et al. Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol Dis 2006, 22:599-610.
15. Cantello R., Gianelli M., Civardi C., et al. Magnetic brain stimulation: the silent period after the motor evoked potential. Neurology 1992, 42:1951-1959.
16. Caramia M.D., Cicinelli P., Paradiso C., et al. Excitability changes of muscular responses to magnetic brain stimulation in patients with central motor disorders. Electroencephalogr Clin Neurophysiol 1991, 81:243-250.
17. Charcot J., Joffroy A. Deux cas d'atrophie musculaire progressive avec lesion de la substance grise et des faisceaux antero-lateraux de la moelle epiniere. Arch Physiol Neurol Pathol 1869, 2:744-754.
18. Cheah B.C., Kiernan M.C. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs 2010, 13:911-920.
19. Cheah B.C., Vucic S., Krishnan A.V., et al. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem 2010, 17:1942-1999.
20. Chen R., Samii A., Canos M., et al. Effects of phenytoin on cortical excitability in humans. Neurology 1997, 49:881-883.
21. Chen R., Tam A., Butefisch C., et al. Intracortical inhibition and facilitation in different representations of the human motor cortex. J Neurophysiol 1998, 80:2870-2881.
22. Chen R., Lozano A.M., Ashby P. Mechanism of the silent period following transcranial magnetic stimulation. Evidence from epidural recordings. Exp Brain Res 1999, 128:539-542.
23. Chen R., Cros D., Curra A., et al. The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol 2008, 119:504-532.
24. Choe C.U., Ehrlich B.E. The inositol 1,4,5-trisphosphate receptor (IP3R) and its regulators: sometimes good and sometimes bad teamwork. Sci STKE 2006, 2006:re15.
25. Choi D.W. Ionic dependence of glutamate neurotoxicity. J Neurosci 1987, 7:369-379.
26. Chou S.M., Norris F.H. Amyotrophic lateral sclerosis: lower motor neuron disease spreading to upper motor neurons. Muscle Nerve 1993, 16:864-869.
27. Chung M.J., Suh Y.L. Ultrastructural changes of mitochondria in the skeletal muscle of patients with amyotrophic lateral sclerosis. Ultrastruct Pathol 2002, 26:3-7.
28. Claus D. Central motor conduction: method and normal results. Muscle Nerve 1990, 13:1125-1132.
29. Connors B.W., Malenka R.C., Silva L.R. Two inhibitory postsynaptic potentials, and GABAA and GABAB receptor-mediated responses in neocortex of rat and cat. J Physiol 1988, 406:443-468.
30. Cudkowicz M., Bozik M.E., Ingersoll E.W., et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011, 17:1652-1656.
31. de Carvalho M., Turkman A., Swash M. Motor responses evoked by transcranial magnetic stimulation and peripheral nerve stimulation in the ulnar innervation in amyotrophic lateral sclerosis: the effect of upper and lower motor neuron lesion. J Neurol Sci 2003, 210:83-90.
32. de Carvalho M., Dengler R., Eisen A., et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008, 119:497-503.
33. Deisz R.A. GABA(B) receptor-mediated effects in human and rat neocortical neurones in vitro. Neuropharmacology 1999, 38:1755-1766.
34. DeJesus-Hernandez M., Mackenzie Ian R., Boeve Bradley F., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-Linked FTD and ALS. Neuron 2011, 72:245-256.
35. Desiato M.T., Caramia M.D. Towards a neurophysiological marker of amyotrophic lateral sclerosis as revealed by changes in cortical excitability. Electroencephalogr Clin Neurophysiol 1997, 105:1-7.
36. Desiato M., Bernardi G., Hagi, et al. Transcranial magnetic stimulation of motor pathways directed to muscles supplied by cranial nerves in ALS. Clin Neurophysiol 2002, 113:132-140.
37. Devanne H., Lavoie B.A., Capaday C. Input-output properties and gain changes in the human corticospinal pathway. Exp Brain Res 1997, 114:329-338.
38. Di Lazzaro V., Restuccia D., Oliviero A., et al. Magnetic transcranial stimulation at intensities below active motor threshold activates intracortical inhibitory circuits. Exp Brain Res 1998, 119:265-268.
39. Di Lazzaro V., Oliviero A., Meglio M., et al. Direct demonstration of the effect of lorazepam on the excitability of the human motor cortex. Clin Neurophysiol 2000, 111:794-799.
40. Di Lazzaro V., Oliviero A., Profice P., et al. Ketamine increases human motor cortex excitability to transcranial magnetic stimulation. J Physiol 2003, 547:485-496.
41. Dugan L.L., Choi D.W. Excitotoxicity, free radicals, and cell membrane changes. Ann Neurol 1994, 35:S17-S21.
42. Eisen A.A., Shtybel W. AAEM minimonograph #35: Clinical experience with transcranial magnetic stimulation. Muscle Nerve 1990, 13:995-1011.
43. Eisen A., Weber M. The motor cortex and amyotrophic lateral sclerosis. Muscle Nerve 2001, 24:564-573.
44. Eisen A., Shytbel W., Murphy K., et al. Cortical magnetic stimulation in amyotrophic lateral sclerosis. Muscle Nerve 1990, 13:146-151.
45. Eisen A., Kim S., Pant B. Amyotrophic lateral sclerosis (ALS): a phylogenetic disease of the corticomotoneuron?. Muscle Nerve 1992, 15:219-224.
46. Eisen A., Pant B., Stewart H. Cortical excitability in amyotrophic lateral sclerosis: a clue to pathogenesis. Can J Neurol Sci 1993, 20:11-16.
47. Eisen A., Entezari-Taher M., Stewart H. Cortical projections to spinal motoneurons: changes with aging and amyotrophic lateral sclerosis. Neurology 1996, 46:1396-1404.
48. Eisen A., Nakajima M., Weber M. Corticomotorneuronal hyper-excitability in amyotrophic lateral sclerosis. J Neurol Sci 1998, 160:S64-S68.
49. Eisen A., Nakajima M., Weber M. Electrophysiological studies of the corticomotoneuron in ALS. Rinsho Shinkeigaku 1999, 39:99.
50. Epstein C.M., Schwartzberg D.G., Davey K.R., et al. Localizing the site of magnetic brain stimulation in humans. Neurology 1990, 40:666-670.
51. Filippini N., Douaud G., Mackay C.E., et al. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology 2010, 75:1645-1652.
52. Fisher R.J., Nakamura Y., Bestmann S., et al. Two phases of intracortical inhibition revealed by transcranial magnetic threshold tracking. Exp Brain Res 2002, 143:240-248.
53. Flament D., Goldsmith P., Buckley C.J., et al. Task dependence of responses in first dorsal interosseous muscle to magnetic brain stimulation in man. J Physiol 1993, 464:361-378.
54. Gibb S.L., Boston-Howes W., Lavina Z.S., et al. A caspase-3-cleaved fragment of the glial glutamate transporter EAAT2 is sumoylated and targeted to promyelocytic leukemia nuclear bodies in mutant SOD1-linked amyotrophic lateral sclerosis. J Biol Chem 2007, 282:32480-32490.
55. Gould T.W., Buss R.R., Vinsant S., et al. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci 2006, 26:8774-8786.
56. Gowers W.R. Manual of Diseases of the Nervous System 1886-88, Churchill, London.
57. Gurney M.E., Cutting F.B., Zhai P., et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996, 39:147-157.
58. Gurney M.E., Fleck T.J., Himes C.S., et al. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998, 50:62-66.
59. Haidet-Phillips A.M., Hester M.E., Miranda C.J., et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 2011, 29:824-828.
60. Hanajima R., Ugawa Y., Terao Y., et al. Ipsilateral cortico-cortical inhibition of the motor cortex in various neurological disorders. J Neurol Sci 1996, 109-116.
61. Hanajima R., Ugawa Y., Terao Y., et al. Paired-pulse magnetic stimulation of the human motor cortex: differences among I waves. J Physiol 1998, 509:607-618.
62. Hanajima R., Furubayashi T., Iwata N.K., et al. Further evidence to support different mechanisms underlying intracortical inhibition of the motor cortex. Exp Brain Res 2003, 151:427-434.
63. Hanajima R., Okabe S., Terao Y., et al. Difference in intracortical inhibition of the motor cortex between cortical myoclonus and focal hand dystonia. Clin Neurophysiol 2008, 119:1400-1407.
64. Hanajima R., Terao Y., Shirota Y., et al. Short-interval intracortical inhibition in Parkinson's disease using anterior-posterior directed currents. Exp Brain Res 2011, 214:317-321.
65. Heath P.R., Tomkins J., Ince P.G., et al. Quantitative assessment of AMPA receptor mRNA in human spinal motor neurons isolated by laser capture microdissection. Neuroreport 2002, 13:1753-1757.
66. Hess C.W., Mills K.R., Murray N.M., et al. Magnetic brain stimulation: central motor conduction studies in multiple sclerosis. Ann Neurol 1987, 22:744-752.
67. Higgins C.M., Jung C., Xu Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci 2003, 4:16.
68. Ilic T.V., Korchounov A., Ziemann U. Complex modulation of human motor cortex excitability by the specific serotonin re-uptake inhibitor sertraline. Neurosci Lett 2002, 319:116-120.
69. Ilic T.V., Meintzschel F., Cleff U., et al. Short-interval paired-pulse inhibition and facilitation of human motor cortex: the dimension of stimulus intensity. J Physiol 2002, 545:153-167.
70. Ilic T.V., Korchounov A., Ziemann U. Methylphenidate facilitates and disinhibits the motor cortex in intact humans. Neuroreport 2003, 14:773-776.
71. Ince P., Stout N., Shaw P., et al. Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol Appl Neurobiol 1993, 19:291-299.
72. Inghilleri M., Berardelli A., Cruccu G., et al. Silent period evoked by transcranial stimulation of the human cortex and cervicomedullary junction. J Physiol 1993, 466:521-534.
73. Inghilleri M., Berardelli A., Marchetti P., et al. Effects of diazepam, baclofen and thiopental on the silent period evoked by transcranial magnetic stimulation in humans. Exp Brain Res 1996, 109:467-472.
74. Ionov I.D. Survey of ALS-associated factors potentially promoting Ca(2+) overload of motor neurons. Amyotroph Lateral Scler 2007, 8:260-265.
75. Kawahara Y., Ito K., Sun H., et al. Glutamate receptors: RNA editing and death of motor neurons. Nature 2004, 427:801.
76. Kiernan J., Hudson A. Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis. Brain 1991, 843-853.
77. Kiernan M.C., Vucic S., Cheah B.C., et al. Amyotrophic lateral sclerosis. Lancet 2011, 377:942-955.
78. Kiers L., Cros D., Chiappa K.H., et al. Variability of motor potentials evoked by transcranial magnetic stimulation. Electroencephalogr Clin Neurophysiol 1993, 89:415-423.
79. Kirkinezos I.G., Bacman S.R., Hernandez D., et al. Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. J Neurosci 2005, 25:164-172.
80. Kleine B.U., Schelhaas H.J., van Elswijk G., et al. Prospective, blind study of the triple stimulation technique in the diagnosis of ALS. Amyotroph Lateral Scler 2010, 11:67-75.
81. Kohara N., Kaji R., Kojima Y., et al. Abnormal excitability of the corticospinal pathway in patients with amyotrophic lateral sclerosis: a single motor unit study using transcranial magnetic stimulation. Electroencephalogr Clin Neurophysiol 1996, 101:32-41.
82. Komissarow L., Rollnik J.D., Bogdanova D., et al. Triple stimulation technique (TST) in amyotrophic lateral sclerosis. Clin Neurophysiol 2004, 115:356-360.
83. Korchounov A., Ilic T.V., Ziemann U. The alpha2-adrenergic agonist guanfacine reduces excitability of human motor cortex through disfacilitation and increase of inhibition. Clin Neurophysiol 2003, 114:1834-1840.
84. Kujirai T., Caramia M.D., Rothwell J.C., et al. Corticocortical inhibition in human motor cortex. J Physiol 1993, 471:501-519.
85. Kwak S., Kawahara Y. Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J Mol Med 2005, 83:110-120.
86. Lacomblez L., Bensimon G., Leigh P.N., et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996, 347:1425-1431.
87. Lederer C.W., Torrisi A., Pantelidou M., et al. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC Genomics 2007, 8:26.
88. Lees G.J. Contributory mechanisms in the causation of neurodegenerative disorders. Neuroscience 1993, 54:287-322.
89. Lemon R.N., Griffiths J. Comparing the function of the corticospinal system in different species: organizational differences for motor specialization?. Muscle Nerve 2005, 32:261-279.
90. Liepert J., Schwenkreis P., Tegenthoff M., et al. The glutamate antagonist riluzole suppresses intracortical facilitation. J Neural Transm 1997, 104:1207-1214.
91. Lillo P., Hodges J.R. Frontotemporal dementia and motor neurone disease: overlapping clinic-pathological disorders. J Clin Neurosci 2009, 16:1131-1135.
92. Macdonell R.A., Shapiro B.E., Chiappa K.H., et al. Hemispheric threshold differences for motor evoked potentials produced by magnetic coil stimulation. Neurology 1991, 41:1441-1444.
93. Magistris M.R., Rosler K.M., Truffert A., et al. Transcranial stimulation excites virtually all motor neurons supplying the target muscle A demonstration and a method improving the study of motor evoked potentials. Brain 1998, 121:437-450.
94. Magistris M.R., Rosler K.M., Truffert A., et al. A clinical study of motor evoked potentials using a triple stimulation technique. Brain 1999, 122:265-279.
95. Maher P., Davis J.B. The role of monoamine metabolism in oxidative glutamate toxicity. J Neurosci 1996, 16:6394-6401.
96. Mavroudakis N., Caroyer J.M., Brunko E., et al. Effects of diphenylhydantoin on motor potentials evoked with magnetic stimulation. Electroencephalogr Clin Neurophysiol 1994, 93:428-433.
97. Meldrum B., Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990, 11:379-387.
98. Meyer B.U., Roricht S., Grafin von Einsiedel H., et al. Inhibitory and excitatory interhemispheric transfers between motor cortical areas in normal humans and patients with abnormalities of the corpus callosum. Brain 1995, 118:429-440.
99. 2+ channels and their regulation by excitatory amino acids. Ann N Y Acad Sci 1989, 568:149-158.
100. Miller R.G., Jackson C.E., Kasarskis E.J., et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009, 73:1227-1233.
101. Mills K.R. Motor neuron disease: Studies of the corticospinal excitation of single motor neurons by magnetic brain stimulation. Brain 1995, 118:971-982.
102. Mills K.R. The natural history of central motor abnormalities in amyotrophic lateral sclerosis. Brain 2003, 126:2558-2566.
103. Mills K. Magnetic stimulation and central conduction time. Clinical Neurophysiology of Motor Neuron Diseases: Handbook of Clinical Neurophysiology Series 2004, Vol. 4:283-293. Elsevier, Amsterdam.
104. Mills K.R., Murray N.M. Electrical stimulation over the human vertebral column: which neural elements are excited?. Electroencephalogr Clin Neurophysiol 1986, 63:582-589.
105. Mills K.R., Nithi K.A. Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis. Muscle Nerve 1997, 20:1137-1141.
106. Miscio G., Pisano F., Mora G., et al. Motor neuron disease: usefulness of transcranial magnetic stimulation in improving the diagnosis. Clin Neurophysiol 1999, 110:975-981.
107. Nakamura H., Kitagawa H., Kawaguchi Y., et al. Intracortical facilitation and inhibition after transcranial magnetic stimulation in conscious humans. J Physiol 1997, 498:817-823.
108. Neumann M., Sampathu D.M., Kwong L.K., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
109. Nihei K., McKee A.C., Kowall N.W. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol (Berl) 1993, 86:55-64.
110. Pachatz C., Terracciano C., Desiato M.T., et al. Upper motor neuron involvement in X-linked recessive bulbospinal muscular atrophy. Clin Neurophysiol 2007, 118:262-268.
111. Pagani M.R., Reisin R.C., Uchitel O.D. Calcium signaling pathways mediating synaptic potentiation triggered by amyotrophic lateral sclerosis IgG in motor nerve terminals. J Neurosci 2006, 26:2661-2672.
112. Pamphlett R., Kril J., Hng T. Motor neuron disease: a primary disorder of corticomotoneurons?. Muscle Nerve 1995, 314-318.
113. Plewnia C., Bartels M., Cohen L., et al. Noradrenergic modulation of human cortex excitability by the presynaptic alpha(2)-antagonist yohimbine. Neurosci Lett 2001, 307:41-44.
114. Plewnia C., Hoppe J., Hiemke C., et al. Enhancement of human cortico-motoneuronal excitability by the selective norepinephrine reuptake inhibitor reboxetine. Neurosci Lett 2002, 330:231-234.
115. Porter R. The Florey Lecture, 1987. Corticomotoneuronal projections: synaptic events related to skilled movement. Proc R Soc Lond B Biol Sci 1987, 231:147-168.
116. Prout A.J., Eisen A. The cortical silent period and ALS. Muscle Nerve 1994, 17:217-223.
117. Pun S., Santos A.F., Saxena S., et al. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci 2006, 9:408-419.
118. Ravits J., Paul P., Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 2007, 68:1571-1575.
119. Regan R.F., Panter S.S., Witz A., et al. Ultrastructure of excitotoxic neuronal death in murine cortical culture. Brain Res 1995, 705:188-198.
120. Renton Alan E., Majounie E., Waite A., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72:257-268.
121. Roshan L., Paradiso G.O., Chen R. Two phases of short-interval intracortical inhibition. Exp Brain Res 2003, 151:330-337.
122. Rossini P.M., Barker A.T., Berardelli A., et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol 1994, 91:79-92.
123. Rossini P.M., Berardelli A., Deuschl G., et al. Applications of magnetic cortical stimulation. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl 1999, 52:171-185.
124. Rothstein J.D., Jin L., Dykes-Hoberg M., et al. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci U S A 1993, 90:6591-6595.
125. Rothstein J.D., Van Kammen M., Levey A.I., et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995, 38:73-84.
126. Rudiak D., Marg E. Finding the depth of magnetic brain stimulation: a re-evaluation. Electroencephalogr Clin Neurophysiol 1994, 93:358-371.
127. Schwenkreis P., Liepert J., Witscher K., et al. Riluzole suppresses motor cortex facilitation in correlation to its plasma level. A study using transcranial magnetic stimulation. Exp Brain Res 2000, 135:293-299.
128. Shaw P., Kuncl R. Current concepts in the pathogenesis of ALS. Motor Neuron Disease 2002, 37-73. WB Saunders, London. W.R. Kuncl (Ed.).
129. Siciliano G., Manca M.L., Sagliocco L., et al. Cortical silent period in patients with amyotrophic lateral sclerosis. J Neurol Sci 1999, 169:93-97.
130. Siebner H.R., Dressnandt J., Auer C., et al. Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia. Muscle Nerve 1998, 21:1209-1212.
131. Simeone T.A., Sanchez R.M., Rho J.M. Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system. J Child Neurol 2004, 19:343-360.
132. Sommer M., Tergau F., Wischer S., et al. Riluzole does not have an acute effect on motor thresholds and the intracortical excitability in amyotrophic lateral sclerosis. J Neurol 1999, 246:III22-III26.
133. Stefan K., Kunesch E., Benecke R., et al. Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis. Ann Neurol 2001, 49:536-539.
134. Takuma H., Kwak S., Yoshizawa T., et al. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol 1999, 46:806-815.
135. Triggs W.J., Macdonell R.A., Cros D., et al. Motor inhibition and excitation are independent effects of magnetic cortical stimulation. Ann Neurol 1992, 32:345-351.
136. Triggs W.J., Kiers L., Cros D., et al. Facilitation of magnetic motor evoked potentials during the cortical stimulation silent period. Neurology 1993, 43:2615-2620.
137. Triggs W.J., Calvanio R., Levine M. Transcranial magnetic stimulation reveals a hemispheric asymmetry correlate of intermanual differences in motor performance. Neuropsychologia 1997, 35:1355-1363.
138. Triggs W.J., Menkes D., Onorato J., et al. Transcranial magnetic stimulation identifies upper motor neuron involvement in motor neuron disease. Neurology 1999, 53:605-611.
139. Trotti D., Rolfs A., Danbolt N.C., et al. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 1999, 2:848.
140. Turner M.R., Kiernan M.C., Leigh P.N., et al. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009, 8:94-109.
141. Urban P.P., Vogt T., Hopf H.C. Corticobulbar tract involvement in amyotrophic lateral sclerosis. A transcranial magnetic stimulation study. Brain 1998, 121:1099-1108.
142. Urban P., Wicht S., Hopf H. Sensitivity of transcranial magnetic stimulation of cortico-bulbar vs. cortico-spinal tract involvement in ALS. J Neurol 2001, 248:850-855.
143. Van Damme P., Van Den Bosch L., Van Houtte E., et al. GluR2-dependent properties of AMPA receptors determine the selective vulnerability of motor neurons to excitotoxicity. J Neurophysiol 2002, 88:1279-1287.
144. Van Damme P., Braeken D., Callewaert G., et al. GluR2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2005, 64:605-612.
145. van Es M.A., Van Vught P.W., Blauw H.M., et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol 2007, 6:869-877.
146. Vucic S., Kiernan M.C. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain 2006, 129:2436-2446.
147. Vucic S., Kiernan M.C. Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2007, 78:849-852.
148. Vucic S., Kiernan M.C. Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol 2008, 119:1088-1096.
149. Vucic S., Kiernan M. Pathophysiology of degeneration in familial amyotrophic lateral sclerosis. Curr Mol Med 2009, 9:255-272.
150. Vucic S., Kiernan M.C. Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry 2010, 81:222-227.
151. Vucic S., Kiernan M. Clarifying variability of corticomotoneuronal function in Kennedy's disease. Muscle Nerve 2011, 44:197-201.
152. Vucic S., Howells J., Trevillion L., et al. Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve 2006, 33:477-486.
153. Vucic S., Burke D., Kiernan M.C. Diagnosis of motor neuron disease. The Motor Neuron Disease Handbook 2007, 89-115. Australasian Medical Publishing Company Limited, Sydney. M.C. Kiernan (Ed.).
154. Vucic S., Nicholson G.A., Kiernan M.C. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008, 131:1540-1550.
155. Vucic S., Cheah B.C., Kiernan M.C. Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Exp Neurol 2009, 220:177-182.
156. Vucic S., Cheah B.C., Krishnan A.V., et al. The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Res 2009, 1273:39-47.
157. Vucic S., Cheah B.C., Yiannikas C., et al. Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain 2010, 133:2727-2733.
158. Vucic S., Nicholson G.A., Kiernan M.C. Cortical excitability in hereditary motor neuronopathy with pyramidal signs: comparison with ALS. J Neurol Neurosurg Psychiatry 2010, 81:97-100.
159. Vucic S., Cheah B.C., Kiernan M.C. Dissecting the mechanisms underlying short-interval intracortical inhibition using exercise. Cereb Cortex 2011, 21:1639-1644.
160. Vucic S., Cheah B.C., Yiannikas C., et al. Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol 2011, 122:1860-1866.
161. Weber M., Eisen A. Assessment of upper and lower motor neurons in Kennedy's disease: implications for corticomotoneuronal PSTH studies. Muscle Nerve 1999, 22:299-306.
162. Weber M., Eisen A., Stewart H., et al. The split hand in ALS has a cortical basis. J Neurol Sci 2000, 180:66-70.
163. Werhahn K.J., Kunesch E., Noachtar S., et al. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol 1999, 517:591-597.
164. Williams T.L., Day N.C., Ince P.G., et al. Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1997, 42:200-207.
165. Winhammar J.M., Rowe D.B., Henderson R.D., et al. Assessment of disease progression in motor neuron disease. Lancet Neurol 2005, 4:229-238.
166. Wittstock M., Wolters A., Benecke R. Transcallosal inhibition in amyotrophic lateral sclerosis. Clin Neurophysiol 2007, 118:301-307.
167. Wittstock M., Meister S., Walter U., et al. Mirror movements in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011, 12:393-397.
168. Xu Z., Jung C., Higgins C., et al. Mitochondrial degeneration in amyotrophic lateral sclerosis. J Bioenerg Biomembr 2004, 36:395-399.
169. Yamauchi H., Fukuyama H., Ouchi Y., et al. Corpus callosum atrophy in amyotrophic lateral sclerosis. J Neurol Sci 1995, 134:189-196.
170. Yokota T., Yoshino A., Inaba A., et al. Double cortical stimulation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1996, 61:596-600.
171. Zanette G., Tamburin S., Manganotti P., et al. Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clin Neurophysiol 2002, 113:1688-1697.
172. Ziemann U. Cortical threshold and excitability measurements. Clinical Neurophysiology of Motor Neuron Diseases: Handbook of Clinical Neurophysiology Series 2004, 317-335. Elsevier, Amsterdam. A. Eisen (Ed.).
173. Ziemann U., Netz J., Szelenyi A., et al. Spinal and supraspinal mechanisms contribute to the silent period in the contracting soleus muscle after transcranial magnetic stimulation of human motor cortex. Neurosci Lett 1993, 156:167-171.
174. Ziemann U., Bruns D., Paulus W. Enhancement of human motor cortex inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation. Neurosci Lett 1996, 208:187-190.
175. Ziemann U., Rothwell J.C., Ridding M.C. Interaction between intracortical inhibition and facilitation in human motor cortex. J Physiol 1996, 496:873-881.
176. Ziemann U., Tergau F., Bruns D., et al. Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. Electroencephalogr Clin Neurophysiol 1997, 105:430-437.
177. Ziemann U., Winter M., Reimers C.D., et al. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Neurology 1997, 49:1292-1298.